Drug intelligence / Profile preview

HLK-6003

Development stage: Preclinical
Lead developer: HLK Pharmacin
Modality: Small Molecules

Overview

HLK-6003 is a pharmaceutical candidate being developed by Pharmacin International (HLK Pharmacin) for the treatment of cancer metastasis. It is being developed via the FDA's 505(b)(2) regulatory pathway, which indicates it is a new formulation, dosage form, or repurposing of a previously approved drug. The asset is currently in the formulation development stage. While the specific active ingredient and molecular target have not been disclosed, the program aims to address the spread of cancer cells to distant organs by optimizing the delivery or efficacy of an existing therapeutic agent.

Beyond the preview

Go deeper on HLK-6003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-6003.

Explore the full profile